cilostazol has been researched along with Ventricular Fibrillation in 10 studies
Ventricular Fibrillation: A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous reports demonstrated that cilostazol, a phosphodiesterase 3 inhibitor, affected cellular electrophysiology and reduced episodes of ventricular fibrillation (VF) in patients with Brugada syndrome." | 7.76 | Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine. ( Chattipakorn, N; Chattipakorn, S; Kanlop, N; Shinlapawittayatorn, K; Sungnoon, R; Weerateerangkul, P, 2010) |
| "Hypothermia has been reported to induce ventricular tachycardia and fibrillation (VT/VF) in patients with early repolarization (ER) pattern." | 5.40 | Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. ( Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B, 2014) |
| "Cilostazol was discontinued 2 days before replacement because of its antiplatelet effects." | 5.40 | Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes. ( Ayabe, R; Ebata, Y; Fukui, A; Nakagawa, M; Okada, N; Shinohara, T; Takahashi, N; Yufu, K, 2014) |
| "Previous reports demonstrated that cilostazol, a phosphodiesterase 3 inhibitor, affected cellular electrophysiology and reduced episodes of ventricular fibrillation (VF) in patients with Brugada syndrome." | 3.76 | Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine. ( Chattipakorn, N; Chattipakorn, S; Kanlop, N; Shinlapawittayatorn, K; Sungnoon, R; Weerateerangkul, P, 2010) |
| "Hypothermia has been reported to induce ventricular tachycardia and fibrillation (VT/VF) in patients with early repolarization (ER) pattern." | 1.40 | Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. ( Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B, 2014) |
| "Cilostazol was discontinued 2 days before replacement because of its antiplatelet effects." | 1.40 | Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes. ( Ayabe, R; Ebata, Y; Fukui, A; Nakagawa, M; Okada, N; Shinohara, T; Takahashi, N; Yufu, K, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, K | 1 |
| Miyazaki, S | 1 |
| Ishikawa, E | 1 |
| Mukai, M | 1 |
| Aoyama, D | 1 |
| Nodera, M | 1 |
| Kaseno, K | 1 |
| Tada, H | 1 |
| Gurabi, Z | 2 |
| Koncz, I | 2 |
| Patocskai, B | 2 |
| Nesterenko, VV | 1 |
| Antzelevitch, C | 2 |
| Shinohara, T | 1 |
| Ebata, Y | 1 |
| Ayabe, R | 1 |
| Fukui, A | 1 |
| Okada, N | 1 |
| Yufu, K | 1 |
| Nakagawa, M | 1 |
| Takahashi, N | 1 |
| Sturm, AC | 1 |
| Kline, CF | 1 |
| Glynn, P | 1 |
| Johnson, BL | 1 |
| Curran, J | 1 |
| Kilic, A | 1 |
| Higgins, RS | 1 |
| Binkley, PF | 1 |
| Janssen, PM | 1 |
| Weiss, R | 1 |
| Raman, SV | 1 |
| Fowler, SJ | 1 |
| Priori, SG | 1 |
| Hund, TJ | 1 |
| Carnes, CA | 1 |
| Mohler, PJ | 1 |
| Barajas-Martinez, H | 1 |
| Hu, D | 1 |
| Jang, SW | 1 |
| Kim, DB | 1 |
| Kwon, BJ | 1 |
| Shin, D | 1 |
| Her, SH | 1 |
| Park, CS | 1 |
| Park, HJ | 1 |
| Park, MW | 1 |
| Cho, EJ | 1 |
| Rho, TH | 1 |
| Kim, JH | 1 |
| Kanlop, N | 1 |
| Shinlapawittayatorn, K | 1 |
| Sungnoon, R | 1 |
| Weerateerangkul, P | 1 |
| Chattipakorn, S | 1 |
| Chattipakorn, N | 1 |
| Iguchi, K | 1 |
| Noda, T | 1 |
| Kamakura, S | 1 |
| Shimizu, W | 1 |
| Tsuchiya, T | 1 |
| Ashikaga, K | 1 |
| Honda, T | 1 |
| Arita, M | 1 |
| Abud, A | 1 |
| Bagattin, D | 1 |
| Goyeneche, R | 1 |
| Becker, C | 1 |
10 other studies available for cilostazol and Ventricular Fibrillation
| Article | Year |
|---|---|
Repetitive shock therapy of subcutaneous implantable cardioverter defibrillators in a patient with idiopathic ventricular fibrillation: What is the mechanism?
Topics: Ablation Techniques; Action Potentials; Anti-Arrhythmia Agents; Cilostazol; Defibrillators, Implanta | 2019 |
Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cilostazol; Disease Models, Animal; Dogs; Electr | 2014 |
Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes.
Topics: Adult; Anti-Arrhythmia Agents; Bepridil; Cilostazol; Death, Sudden, Cardiac; Dose-Response Relations | 2014 |
Use of whole exome sequencing for the identification of Ito-based arrhythmia mechanism and therapy.
Topics: 4-Aminopyridine; Action Potentials; Adult; Cilostazol; Dipeptidyl-Peptidases and Tripeptidyl-Peptida | 2015 |
Cellular and ionic mechanisms underlying the effects of cilostazol, milrinone, and isoproterenol to suppress arrhythmogenesis in an experimental model of early repolarization syndrome.
Topics: Action Potentials; Animals; Cardiac Electrophysiology; Cardiovascular Agents; Cilostazol; Death, Sud | 2016 |
Death caused by simultaneous subacute stent thrombosis of sirolimus-eluting stents in left anterior descending artery and left circumflex artery.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Occ | 2010 |
Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cilostazol; Electric Countershock; Female; He | 2010 |
Beneficial effects of cilostazol in a patient with recurrent ventricular fibrillation associated with early repolarization syndrome.
Topics: Cilostazol; Combined Modality Therapy; Defibrillators, Implantable; Drug Therapy, Combination; Elect | 2013 |
Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome.
Topics: Administration, Oral; Aged; Bundle-Branch Block; Cilostazol; Electrocardiography; Humans; Male; Phos | 2002 |
Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Cilostazol; Defibrillators, Implantable; Electro | 2006 |